Loading organizations...
Founding partners Yu Minhong, founder of New Oriental Education, and Sheng Xitai, former chairman of Huatai United Securities, established Hongtai Fund in Beijing, China, in 2014. This prominent venture capital firm, also known as Hongtai Aplus, specializes in early-stage startup investments and provides comprehensive full life-cycle investment management, targeting promising Chinese entrepreneurs. Hongtai Fund strategically focuses on high-growth sectors such as information technology, advanced manufacturing, pharmacy & medical care, consumption & education, and new materials, with additional emphasis on media, culture, education, entertainment, high-tech, and mobile internet. The firm demonstrates significant scale and a robust investment strategy, managing approximately RMB 30 billion in assets under management (AUM). As of May 2024, it has successfully closed 6 funds, with one additional fund currently in market, reflecting its continuous engagement in the venture landscape. Notably, Sheng Xitai was recognized as one of China's top 30 best early investors in September 2018.
Hongtai Fund has 4 tracked investments across 4 companies. The latest tracked deal is $5.1B Series C in Regend Therapeutics in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2026 | Regend Therapeutics | $5.1B Series C | — | FIR Brook Capital, Gongqingcheng Fuhui, Yuze Capital, 合肥产投, 合肥高投, 天士力资本 |
| Jan 24, 2024 | Orienspace | $83.6M Series B | Hongtai Fund | — |
| Nov 15, 2023 | Aroptics Tech | $27.6M Series C | Hongtai Fund | — |
| Sep 19, 2020 | TargetRx | $14.8M Other Equity | Hongtai Fund | — |